Serum metabolic biomarkers distinguish metabolically healthy peripherally obese from unhealthy centrally obese individuals

Abstract

BackgroundMetabolic abnormalities are more associated with central obesity than peripheral obesity, but the underlying mechanisms are largely unknown. The present study was to identify serum metabolic biomarkers which distinguish metabolically unhealthy centrally obese (MUCO) from metabolically healthy peripherally obese (MHPO) individuals.MethodsA two-stage case–control study design was employed. In the discovery stage, 20 individuals (10 MHPO and 10 MUCO) were included and in the following validation stage, 79 individuals (20 normal weight (NW), 30 MHPO, 29 MUCO) were utilized. Study groups were matched for age, sex, physical activity and total dietary calorie intake with MHPO and MUCO additionally matched for BMI. Metabolic abnormality was defined as: 1) HOMA-IR > 4.27 (90th percentile), 2) high-density lipoprotein cholesterol < 1.03 mmol/L in men and < 1.30 mmol/L in women, 3) fasting blood glucose ≥ 5.6 mmol/L, and 4) waist circumference > 102 cm in men and > 88 cm in women. MUCO individuals had all of these abnormalities whereas MHPO and NW individuals had none of them. A targeted metabolomics approach was performed on fasting serum samples, which can simultaneously identify and quantify 186 metabolites.ResultsIn the discovery stage, serum leucine, isoleucine, tyrosine, valine, phenylalanine, alpha-aminoadipic acid, methioninesulfoxide and propionylcarnitine were found to be significantly higher in MUCO, compared with MHPO group after multiple testing adjustment. Significant changes of five metabolites (leucine, isoleucine, valine, alpha-aminoadipic acid, propionylcarnitine) were confirmed in the validation stage.ConclusionsSignificantly higher levels of serum leucine, isoleucine, valine, alpha-aminoadipic acid, propionylcarnitine are characteristic of metabolically unhealthy centrally obese patients. The finding provides novel insights into the pathogenesis of metabolic abnormalities in obesity.Electronic supplementary materialThe online version of this article (doi:10.1186/s12986-016-0095-9) contains supplementary material, which is available to authorized users.

Metabolically healthy obese women have longer telomere length than obese women with metabolic syndrome

“…Also, when we evaluated the insulin resistance, we found that MHO had significantly lower HOMA index compared to MSO patients, and that MHO and MHNO did not differ with respect to insulin sensibility. Similar results have been published in metabolically healthy peripherally obese [30]. …”

Metabolomic profiling identifies potential pathways involved in the interaction of iron homeostasis with glucose metabolism

“…Although these observations suggest that iron and glucose or lipid homeostasis interact at the molecular level, data on the site of these interactions have remained scarce in humans. Profiling of the serum metabolome has been used as a valuable tool to identify subtle changes in various diseases such as cancer, cardiovascular diseases, or obesity [43], [44], [45].…”

Metabolomic Profiles of Overweight/Obesity Phenotypes During Adolescence: A Cross‐Sectional Study in Project Viva

“…Metabolomics, or the systematic and comprehensive study of low molecular weight compounds in biological tissues and fluids, has emerged as a powerful tool to refine our knowledge of more nuanced differences in metabolic phenotypes. To date, a handful of small studies in adults have used metabolomics to characterize differences in circulating metabolites that differ between metabolically healthy versus metabolically unhealthy obesity in adult populations . These studies have identified differences in compounds on branched‐chain amino acid (BCAA) and lipid metabolism pathways between metabolically healthy versus unhealthy obesity.…”